Merus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
CEOSven Ante Lundberg
CEOSven Ante Lundberg
Employees260
Employees260
HeadquartersUtrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded2003
Founded2003
Employees260
Employees260
MRUS Key Statistics
Market cap7.30B
Market cap7.30B
Price-Earnings ratio-18.04
Price-Earnings ratio-18.04
Dividend yield—
Dividend yield—
Average volume1.40M
Average volume1.40M
High today$96.27
High today$96.27
Low today$96.02
Low today$96.02
Open price$96.11
Open price$96.11
Volume1.42M
Volume1.42M
52 Week high$96.28
52 Week high$96.28
52 Week low$33.19
52 Week low$33.19
Stock Snapshot
Merus(MRUS) stock is priced at $96.23, giving the company a market capitalization of 7.3B. It carries a P/E multiple of -18.04.
As of 2025-12-05, Merus(MRUS) stock has fluctuated between $96.02 and $96.27. The current price stands at $96.23, placing the stock +0.2% above today's low and -0.0% off the high.
Merus(MRUS) shares are trading with a volume of 1.42M, against a daily average of 1.4M.
During the past year, Merus(MRUS) stock moved between $33.19 at its lowest and $96.28 at its peak.
During the past year, Merus(MRUS) stock moved between $33.19 at its lowest and $96.28 at its peak.
Analyst ratings
88%
of 17 ratingsBuy
11.8%
Hold
88.2%
Sell
0%
People also own
Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.